Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Palivizumab Stories

2013-09-19 23:24:29

Reportbuyer.com just published a new market research report: PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - Current and Future Players. London (PRWEB) September 19, 2013 Summary GlobalData has released its pharma report, “PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing RSV Market. The...

2013-09-18 23:04:40

Reportbuyer.com just published a new market research report: Synagis (Pediatric RSV) - Forecast and Market Analysis to 2022 London (PRWEB) September 18, 2013 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Synagis (Pediatric RSV) - Forecast and Market Analysis to 2022”. Respiratory syncytial virus (RSV) is a common cause of pediatric respiratory infections and virtually all children will have been infected by the virus by the age of two. RSV transmission...

2013-09-18 23:02:47

Reportbuyer.com just published a new market research report: PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - US Drug Forecast and Market Analysis to 2022 London (PRWEB) September 18, 2013 Summary Respiratory syncytial virus (RSV) is a common cause of pediatric respiratory infections and virtually all children will have been infected by the virus by the age of two. RSV transmission typically occurs during the winter and early spring months. The virus is spread...

2013-08-12 23:22:27

A safe and protective intranasal RSV vaccine (SynGEM®) based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles. Groningen, the Netherlands (PRWEB) August 12, 2013 Biotechnology company Mucosis B.V. today announced the publication in the peer-reviewed journal PLOS ONE of preclinical data showing that its innovative SynGEM® is safe and protective in animal models. According to the report, SynGEM®, a vaccine based on the Mimopath®...

2013-05-04 12:22:20

GAITHERSBURG, Md., May 4, 2013 /PRNewswire/ -- MedImmune announced today it will conduct seven poster and/or presentations at the Pediatric Academic Societies (PAS) Meeting at the Walter E. Washington Convention Center in Washington DC, May 4-7, 2013. These abstracts advance the body of existing data and knowledge around influenza and respiratory syncytial virus (RSV) prevention, highlighting MedImmune's continued commitment to patient health. MedImmune posters to be presented at PAS...

2012-10-03 06:25:54

GAITHERSBURG, Md., Oct. 3, 2012 /PRNewswire/ -- MedImmune, the biologics arm of AstraZeneca, today announced that the Journal of Medical Economics has published a study that shows Synagis® (palivizumab) is within the acceptable range of cost effectiveness. Specifically, the study relates to Synagis' reduction in hospitalizations due to serious respiratory syncytial virus (RSV) disease among eligible preterm infant populations covered by Medicaid and private insurers in the United States...

2012-05-01 06:27:25

BOSTON, May 1, 2012 /PRNewswire/ -- MedImmune, the global biologics arm of AstraZeneca, announced results from a new retrospective database cohort study of 8,443 high-risk infants receiving palivizumab in Medicaid programs across 12 states. Approximately 67% of infants were non-compliant with palivizumab. Non-compliance with the FDA-approved dosing of Synagis® (palivizumab), defined as not receiving at least 5 doses or having dosing gaps, significantly increased likelihood of...

2012-04-10 02:26:17

NEWARK, Del., April 10, 2012 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) announced that its proprietary iBioLaunch(TM) technology for the production of biotherapeutic proteins and vaccine antigens in whole green plants has been used to produce a functional monoclonal antibody copy of palivizumab, a humanized monoclonal antibody that binds to respiratory syncytial virus (RSV) glycoprotein fusion protein (F), and inhibits viral entry into cells. Palivizumab is used to reduce RSV associated...

2011-10-20 09:00:00

ST. PAUL, Minn., Oct. 20, 2011 /PRNewswire/ -- Children given an injectable medication to help prevent severe respiratory illness had a 17.6 percent higher likelihood of receiving the American Academy of Pediatrics (AAP) recommended doses when they were administered through a specialty pharmacy rather than a traditional pharmacy, according to a new study released today by pharmacy benefit manager Prime Therapeutics (Prime). The study will be presented today at the Academy of Managed Care...

2011-09-27 14:41:00

SILVER SPRING, Md., Sept. 27, 2011 /PRNewswire/ -- The National Medical Association (NMA) is the nation's oldest and largest association of African American (AA) physicians and is issuing a "Call to Action" regarding Respiratory Synctial Virus (RSV), an infection that is a major cause of respiratory illness in infants and young children. RSV causes an estimated 90,000 hospitalizations and 4,500 deaths per year in children 5 years of age and younger. In collaboration with the National...